News & Events
-
Brain Mets Basics for NSCLC: What Are Brain Metastases and How Do We Treat Them?
Read time: 2 minutes.
Brain metastases (also called brain mets) develop when cancer from somewhere else in the body spreads to the brain.
Over time, tumors can become metastatic (travel to other...
-
Research Milestones: Celebrating LUNGevity’s 2024 Research Awards
LUNGevity had a tremendous year supporting impactful research in 2024. In addition to our existing portfolio of ongoing research grants, we issued several new research awards in... -
Celebrating 20 Years of Progress in Lung Cancer Research and Treatment
Read time: 5 minutes. This year marks 20 years since researchers made a key discovery that changed the face of lung cancer research and treatment. By uncovering EGFR’s role in lung... -
Screening and Early Detection of Lung Cancer: Highlights from WCLC and ESMO 2024
Lung cancer screening and early detection were major topics of discussion at the World Conference on Lung Cancer (WCLC), held in San Diego from September 7-10, and the European... -
Metastatic Non-Small Cell Lung Cancer: Highlights from WCLC and ESMO 2024
This year, the first three weeks of September were packed with lung cancer research updates at the World Conference on Lung Cancer (WCLC) from September 7-10 in San Diego followed... -
Eating Healthy on the Mediterranean Diet
Read time: 3 minutes. Oncology dietitian Lori Bumbaco takes us on a culinary journey, exploring why experts consistently rank the Mediterranean diet as the number one choice for... -
How Do Drugs Get Approved (and Fast-Tracked) by the FDA?
Read time: 5 minutes. This is Part 3 in our series on how drugs get approved to treat lung cancer. Part 1: Understanding Clinical Trials - Why Are They Important for Drug... -
How We Define Success for a Clinical Trial
Read time: 6 minutes. This is Part 2 of 3 in our series on how drugs get approved to treat lung cancer. Make sure to read Part 1 on the phases of clinical trials and why they are... -
Understanding Clinical Trials: Why Are They Important for Drug Development?
Read time: 3 minutes. This is Part 1 in a 3-part series explaining how new drugs and treatments get approved to treat lung cancer. Parts 2 and 3 will be published in the coming... -
KRAS Virtual Meetup
Join us the 3rd Wednesday of every month to c onnect with others who share common experiences and build your community. After registering, you will receive a confirmation email...
Laurie’s Path to Finding the Right Doctor, the Right Test, and the Right Treatment
Laurie’s Path to Finding the Right Doctor, the Right Test, and the Right Treatment
Laurie Seligman, a 57-year-old bookkeeper living in Texas, had a lingering cough, but over-the-counter cough syrup seemed to help, so she didn’t think much of it and she continued with her usual activities. One day in 2017, she hurt her back moving a heavy bed, and went to her general care doctor. She mentioned the cough and got an X-ray. After being treated for pneumonia, her symptoms subsided. She had a follow-up X-ray but was told that it was normal for the pneumonia to still be visible…
Linda I. Shares Her Story
Linda I. Shares Her Story
I was told on October 11, 2007, that I had non-small cell lung cancer (NSCLC). I was 46 years old with 2 kids — 7 and 12 year olds — at home waiting for me.I had an MRI and PET scan and had my second lung cancer diagnosis. I went to Lombardi Cancer Center in Georgetown (Washington, DC) and they took care of me. Those amazing people guided me on my journey with bilateral lung cancer.I was not aware of biomarkers back then, but I had bilateral thoracotomies and chemotherapy.I survived.…
Let Your Voice Be Heard!
Let Your Voice Be Heard!
We are collecting stories from patients, caregivers, friends, and family members! Tell us how lung cancer has affected your life. Email your story to us at support@lungevity.org. Thanks!
All About Biomarker Testing & KRAS+ Lung Cancer
All About Biomarker Testing & KRAS+ Lung Cancer
Patient Rosemary Conway was joined by LUNGevity's Dr. Amy Moore and Hatim Husain, an oncologist at UCSD, to discuss biomarker testing and progress in KRAS-positive lung cancer.